KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Other Non-Current Assets (2016 - 2025)

Amgen has reported Other Non-Current Assets over the past 17 years, most recently at $12.7 billion for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $12.7 billion for Q4 2025, up 27.49% from a year ago — trailing twelve months through Dec 2025 was $12.7 billion (up 27.49% YoY), and the annual figure for FY2025 was $12.7 billion, up 27.49%.
  • Other Non-Current Assets for Q4 2025 was $12.7 billion at Amgen, down from $13.2 billion in the prior quarter.
  • Over the last five years, Other Non-Current Assets for AMGN hit a ceiling of $13.2 billion in Q3 2025 and a floor of $5.8 billion in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $7.7 billion (2023), compared with a mean of $8.4 billion.
  • Biggest five-year swings in Other Non-Current Assets: decreased 9.58% in 2022 and later soared 62.93% in 2023.
  • Amgen's Other Non-Current Assets stood at $6.5 billion in 2021, then fell by 9.58% to $5.9 billion in 2022, then soared by 62.93% to $9.6 billion in 2023, then rose by 3.32% to $9.9 billion in 2024, then rose by 27.49% to $12.7 billion in 2025.
  • The last three reported values for Other Non-Current Assets were $12.7 billion (Q4 2025), $13.2 billion (Q3 2025), and $11.0 billion (Q2 2025) per Business Quant data.